BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
-16.23%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$1.45B
AUM Growth
-$125M
(-8%)
Cap. Flow
+$148M
Cap. Flow
% of AUM
10.17%
Top 10 Holdings %
Top 10 Hldgs %
37.98%
Holding
149
New
10
Increased
70
Reduced
43
Closed
11
Top Buys
| 1 |
Align Technology
ALGN
|
$34.4M |
| 2 |
Illumina
ILMN
|
$31.2M |
| 3 |
Intuitive Surgical
ISRG
|
$24.4M |
| 4 |
Teladoc Health
TDOC
|
$24.2M |
| 5 |
Abbott
ABT
|
$15.2M |
Top Sells
| 1 |
KTWO
K2M Group Holdings, Inc
KTWO
|
$15.1M |
| 2 |
Centene
CNC
|
$14.7M |
| 3 |
Edwards Lifesciences
EW
|
$14.6M |
| 4 |
Pacific Biosciences
PACB
|
$13.9M |
| 5 |
SHPG
Shire pic
SHPG
|
$11.6M |
Sector Composition
| 1 | Healthcare | 92.41% |
| 2 | Industrials | 1.04% |
| 3 | Technology | 0.54% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
AngioDynamics
ANGO
$432M
| $1.52M | 0.1% |
75,700
| – | – |
|
102
FibroGen
FGEN
$48.4M
| $1.48M | 0.1% |
+1,280
| New | +$1.48M |
|
103
Insulet
PODD
$24.2B
| $1.43M | 0.09% |
18,000
| – | – |
|
104
Sarepta Therapeutics
SRPT
$1.98B
| $1.39M | 0.09% |
12,700
-400
| -3% | -$43.7K |
|
|
VCRA
105
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
| $1.3M | 0.09% |
+32,950
| New | +$1.3M |
|
106
Amneal Pharmaceuticals
AMRX
$3B
| $1.29M | 0.08% |
95,000
| – | – |
|
|
BLUE
107
DELISTED
bluebird bio
BLUE
| $1.28M | 0.08% |
996
+116
| +13% | +$149K |
|
|
ENDP
108
DELISTED
Endo International plc
ENDP
| $1.24M | 0.08% |
170,392
-47,000
| -22% | -$343K |
|
109
argenx
ARGX
$44.2B
| $1.21M | 0.08% |
+12,600
| New | +$1.21M |
|
|
LOXO
110
DELISTED
Loxo Oncology, Inc
LOXO
| $1.21M | 0.08% |
+8,600
| New | +$1.21M |
|
|
ARNA
111
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $1.18M | 0.08% |
30,317
-500
| -2% | -$19.5K |
|
112
Merck
MRK
$210B
| $1.15M | 0.08% |
15,720
+2,620
| +20% | +$191K |
|
|
MRTX
113
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $1.02M | 0.07% |
24,000
-1,000
| -4% | -$42.4K |
|
|
SAGE
114
DELISTED
Sage Therapeutics
SAGE
| $1.02M | 0.07% |
10,600
-600
| -5% | -$57.5K |
|
115
Regenxbio
RGNX
$498M
| $977K | 0.06% |
23,300
| – | – |
|
116
Ultragenyx Pharmaceutical
RARE
$3.04B
| $965K | 0.06% |
22,200
-9,650
| -30% | -$419K |
|
117
Myriad Genetics
MYGN
$633M
| $927K | 0.06% |
+31,900
| New | +$927K |
|
118
Teva Pharmaceuticals
TEVA
$21.5B
| $925K | 0.06% |
60,000
| – | – |
|
119
Evolent Health
EVH
$1.11B
| $903K | 0.06% |
+45,270
| New | +$903K |
|
120
Labcorp
LH
$22.8B
| $821K | 0.05% |
7,566
-101,897
| -93% | -$11.1M |
|
121
Ironwood Pharmaceuticals
IRWD
$201M
| $793K | 0.05% |
91,341
-3,463
| -4% | -$30.1K |
|
|
CLLS
122
Cellectis
CLLS
$260M
| $778K | 0.05% |
46,750
-2,850
| -6% | -$47.4K |
|
123
McKesson
MCK
$85.9B
| $760K | 0.05% |
6,879
-1,624
| -19% | -$179K |
|
|
ADAP
124
Adaptimmune Therapeutics
ADAP
$13.9M
| $754K | 0.05% |
131,135
+72,600
| +124% | +$417K |
|
125
PTC Therapeutics
PTCT
$4.41B
| $745K | 0.05% |
21,700
-800
| -4% | -$27.5K |
|